CA2539501A1 - Nanoparticle conjugates and method of production thereof - Google Patents
Nanoparticle conjugates and method of production thereof Download PDFInfo
- Publication number
- CA2539501A1 CA2539501A1 CA002539501A CA2539501A CA2539501A1 CA 2539501 A1 CA2539501 A1 CA 2539501A1 CA 002539501 A CA002539501 A CA 002539501A CA 2539501 A CA2539501 A CA 2539501A CA 2539501 A1 CA2539501 A1 CA 2539501A1
- Authority
- CA
- Canada
- Prior art keywords
- nanoparticle
- peptide
- nanoparticles
- nanoparticle conjugate
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 386
- 238000000034 method Methods 0.000 title claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 215
- 239000003446 ligand Substances 0.000 claims abstract description 86
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 61
- 235000018417 cysteine Nutrition 0.000 claims abstract description 15
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 6
- 239000010931 gold Substances 0.000 claims description 42
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 28
- 230000015572 biosynthetic process Effects 0.000 claims description 27
- 229910052737 gold Inorganic materials 0.000 claims description 26
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000003786 synthesis reaction Methods 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 18
- 125000000524 functional group Chemical group 0.000 claims description 17
- 229960002685 biotin Drugs 0.000 claims description 14
- 235000020958 biotin Nutrition 0.000 claims description 14
- 239000011616 biotin Substances 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 108090001008 Avidin Proteins 0.000 claims description 12
- 150000003573 thiols Chemical class 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 108010090804 Streptavidin Proteins 0.000 claims description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000002953 phosphate buffered saline Substances 0.000 claims description 7
- 238000000429 assembly Methods 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 230000004001 molecular interaction Effects 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 239000004065 semiconductor Substances 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 6
- -1 antibodies Proteins 0.000 claims description 5
- 230000000712 assembly Effects 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 229910017052 cobalt Inorganic materials 0.000 claims description 5
- 239000010941 cobalt Substances 0.000 claims description 5
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 5
- 238000013537 high throughput screening Methods 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 230000001808 coupling effect Effects 0.000 claims description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 230000003019 stabilising effect Effects 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000005083 Zinc sulfide Substances 0.000 claims description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 claims description 2
- 230000002559 cytogenic effect Effects 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000696 magnetic material Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 238000001742 protein purification Methods 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 claims description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 239000007769 metal material Substances 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 239000002245 particle Substances 0.000 description 54
- 238000002474 experimental method Methods 0.000 description 31
- 230000002776 aggregation Effects 0.000 description 25
- 238000004220 aggregation Methods 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 17
- 230000003993 interaction Effects 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000002209 hydrophobic effect Effects 0.000 description 13
- 230000007774 longterm Effects 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000012071 phase Substances 0.000 description 11
- 230000006641 stabilisation Effects 0.000 description 11
- 229920002971 Heparan sulfate Polymers 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 238000001209 resonance light scattering Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002094 self assembled monolayer Substances 0.000 description 4
- 239000013545 self-assembled monolayer Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 229920002271 DEAE-Sepharose Polymers 0.000 description 3
- 101000597662 Homo sapiens Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Proteins 0.000 description 3
- 102100035348 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002122 magnetic nanoparticle Substances 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 108700005102 CALNN peptide Proteins 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000003340 combinatorial analysis Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002730 mercury Chemical class 0.000 description 2
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000002109 single walled nanotube Substances 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- DYAOREPNYXXCOA-UHFFFAOYSA-N 2-sulfanylundecanoic acid Chemical compound CCCCCCCCCC(S)C(O)=O DYAOREPNYXXCOA-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010007337 Azurin Proteins 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 229910021503 Cobalt(II) hydroxide Inorganic materials 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- UBEWDCMIDFGDOO-UHFFFAOYSA-N cobalt(II,III) oxide Inorganic materials [O-2].[O-2].[O-2].[O-2].[Co+2].[Co+3].[Co+3] UBEWDCMIDFGDOO-UHFFFAOYSA-N 0.000 description 1
- ASKVAEGIVYSGNY-UHFFFAOYSA-L cobalt(ii) hydroxide Chemical compound [OH-].[OH-].[Co+2] ASKVAEGIVYSGNY-UHFFFAOYSA-L 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- OIZJPMOIAMYNJL-UHFFFAOYSA-H gold(3+);trisulfate Chemical compound [Au+3].[Au+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OIZJPMOIAMYNJL-UHFFFAOYSA-H 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 230000000598 lipoate effect Effects 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000013528 metallic particle Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- QBVXKDJEZKEASM-UHFFFAOYSA-M tetraoctylammonium bromide Chemical compound [Br-].CCCCCCCC[N+](CCCCCCCC)(CCCCCCCC)CCCCCCCC QBVXKDJEZKEASM-UHFFFAOYSA-M 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0321937.5 | 2003-09-19 | ||
| GBGB0321937.5A GB0321937D0 (en) | 2003-09-19 | 2003-09-19 | Nanoparticle conjugates and method of production thereof |
| PCT/GB2004/003986 WO2005029076A2 (en) | 2003-09-19 | 2004-09-20 | Nanoparticle conjugates and method of production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2539501A1 true CA2539501A1 (en) | 2005-03-31 |
Family
ID=29266267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002539501A Abandoned CA2539501A1 (en) | 2003-09-19 | 2004-09-20 | Nanoparticle conjugates and method of production thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070054337A1 (enExample) |
| EP (1) | EP1664776A2 (enExample) |
| JP (1) | JP2007506084A (enExample) |
| AU (1) | AU2004274694A1 (enExample) |
| CA (1) | CA2539501A1 (enExample) |
| GB (1) | GB0321937D0 (enExample) |
| WO (1) | WO2005029076A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9434770B2 (en) * | 2004-10-07 | 2016-09-06 | Tapas K Das Gupta | Modified cupredoxin derived peptides |
| JP5059312B2 (ja) * | 2005-09-16 | 2012-10-24 | Ｈｏｙａ株式会社 | 高分散性リン酸カルシウム系化合物ナノ粒子及びその製造方法 |
| KR100713745B1 (ko) * | 2006-02-27 | 2007-05-07 | 연세대학교 산학협력단 | 상전이 리간드로 코팅된 수용성 자성 또는 금속 산화물나노입자 및 이의 제조방법 |
| KR20090059148A (ko) | 2006-09-11 | 2009-06-10 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 쿠프레독신 유래된 펩티드의 변형 및 이의 이용 방법 |
| JP5746469B2 (ja) | 2006-10-04 | 2015-07-08 | ブルックヘブン サイエンス アソシエイツ | Ｄｎａによって導かれたナノ粒子凝集 |
| WO2008134586A1 (en) * | 2007-04-27 | 2008-11-06 | The Regents Of The University Of California | Site-specific conjugation of ligands to nanoparticles |
| WO2009002837A1 (en) * | 2007-06-26 | 2008-12-31 | Massachusetts Institute Of Technology | Controlled modification of semiconductor nanocrystals |
| CN101113457B (zh) * | 2007-07-04 | 2010-05-19 | 中国科学院长春应用化学研究所 | 富精氨酸寡肽-金纳米粒子细胞传输载体合成方法 |
| EP2240782A2 (en) * | 2008-02-04 | 2010-10-20 | Ulive Enterprises Limited | Nanoparticle conjugates |
| US8729012B2 (en) * | 2008-06-02 | 2014-05-20 | Brookhaven Science Associates, Llc | Controllable assembly and disassembly of nanoparticle systems via protein and DNA agents |
| KR101014246B1 (ko) * | 2008-07-03 | 2011-02-16 | 포항공과대학교 산학협력단 | 페하 민감성 금속 나노 입자 및 이의 제조 방법. |
| US20100261185A1 (en) | 2009-03-27 | 2010-10-14 | Life Technologies Corporation | Labeled enzyme compositions, methods and systems |
| WO2011011631A2 (en) * | 2009-07-22 | 2011-01-27 | Samuel Zalipsky | Nucleic acid delivery vehicles |
| WO2011031478A1 (en) * | 2009-08-27 | 2011-03-17 | Brown University | Fe3o4-m(au-like)-nanoparticles for antibody-conserving target-specific platin delivery |
| US8378075B2 (en) * | 2009-10-27 | 2013-02-19 | The United States Of America, As Represented By The Secretary Of The Navy | Covalent attachment of peptides and biological molecules to luminescent semiconductor nanocrystals |
| US9114107B2 (en) | 2010-10-05 | 2015-08-25 | Drexel University | Compositions for inhibiting virus entry and promoting virolysis, and methods thereof |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| DK3489685T3 (da) | 2011-11-21 | 2023-12-04 | Zoetis Services Llc | Signalforstærkning i sidestrømning og tilsvarende immunoassays |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| GB201209517D0 (en) * | 2012-05-29 | 2012-07-11 | Univ Birmingham | Nanoparticles |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| CN102896325B (zh) * | 2012-10-12 | 2014-04-16 | 江南大学 | 一种基于无机小分子盐的金纳米棒手性自组装材料制备方法 |
| CN103058133B (zh) * | 2013-01-30 | 2014-01-08 | 江南大学 | 一种基于非手性小分子组装手性纳米材料的制备方法 |
| US9234078B2 (en) | 2013-03-21 | 2016-01-12 | The Regents Of The University Of Michigan | Conjugated gold nanoparticles |
| US9233138B2 (en) | 2013-10-22 | 2016-01-12 | Drexel University | Compositions for promoting HIV-1 virolysis and methods using same |
| SG10201912301XA (en) | 2013-11-04 | 2020-02-27 | Uti Lp | Methods and compositions for sustained immunotherapy |
| TWI691716B (zh) | 2014-08-13 | 2020-04-21 | 美商艾巴希斯公司 | 電漿特異性結合搭配物檢定中之信號放大 |
| US12011480B2 (en) | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| JP6944438B2 (ja) | 2015-08-04 | 2021-10-06 | ゾエティス サービシズ リミテッド ライアビリティ カンパニー | 溶液ベースのプラズモン特異的結合パートナーアッセイにおけるシグナル増幅 |
| WO2018094213A1 (en) * | 2016-11-18 | 2018-05-24 | Kansas State University Research Foundation | Microfluidics-based nanobiosensors and devices |
| KR102654470B1 (ko) | 2017-01-30 | 2024-04-05 | 조에티스 서비시즈 엘엘씨 | 용액-기반 플라스몬 특이적-결합 파트너 검정 및 금속성 나노구조체 |
| CN111741746A (zh) | 2017-11-29 | 2020-10-02 | 乌第有限合伙公司 | 治疗自身免疫性疾病的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6121425A (en) * | 1994-07-29 | 2000-09-19 | Nanoprobes, Inc. | Metal-lipid molecules |
| US6368877B1 (en) * | 1997-06-25 | 2002-04-09 | Massachusetts Institute Of Technology | Self-assembling peptide surfaces for cell patterning and interactions |
| US6086881A (en) * | 1998-05-15 | 2000-07-11 | Children's Medical Center Corp. | Spatially aligned conjugated composition having a thioether bond linkage |
| US6953656B2 (en) * | 2000-07-14 | 2005-10-11 | Massachusetts Institute Of Technology | Direct, externally imposed control of polypeptides |
-
2003
- 2003-09-19 GB GBGB0321937.5A patent/GB0321937D0/en not_active Ceased
-
2004
- 2004-09-20 EP EP04768532A patent/EP1664776A2/en not_active Withdrawn
- 2004-09-20 AU AU2004274694A patent/AU2004274694A1/en not_active Abandoned
- 2004-09-20 US US10/572,435 patent/US20070054337A1/en not_active Abandoned
- 2004-09-20 WO PCT/GB2004/003986 patent/WO2005029076A2/en not_active Ceased
- 2004-09-20 CA CA002539501A patent/CA2539501A1/en not_active Abandoned
- 2004-09-20 JP JP2006526693A patent/JP2007506084A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004274694A1 (en) | 2005-03-31 |
| US20070054337A1 (en) | 2007-03-08 |
| GB0321937D0 (en) | 2003-10-22 |
| JP2007506084A (ja) | 2007-03-15 |
| WO2005029076A2 (en) | 2005-03-31 |
| EP1664776A2 (en) | 2006-06-07 |
| WO2005029076A3 (en) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2539501A1 (en) | Nanoparticle conjugates and method of production thereof | |
| US20110165647A1 (en) | Nanoparticle conjugates | |
| Gu et al. | Biofunctional magnetic nanoparticles for protein separation and pathogen detection | |
| Matsunaga et al. | Biotechnological application of nano-scale engineered bacterial magnetic particles | |
| US20080241964A1 (en) | Material for improving sensitivity of magnetic sensor and method thereof | |
| KR102021663B1 (ko) | 자성비드 기반의 효소 모방 나노자임을 이용한 타켓 물질의 검출 방법 | |
| US20080153082A1 (en) | Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes | |
| US20120202218A1 (en) | Detection method and device based on nanoparticle aggregation | |
| US20120156686A1 (en) | Multifunctional particles providing cellular uptake and magnetic motor effect | |
| KR20040083095A (ko) | 페라이트 결합 유기 물질 및 이의 제조 방법 | |
| JP2006508095A (ja) | 粒子の生物活性化 | |
| Wang et al. | Surface modification and bioconjugation of FeCo magnetic nanoparticles with proteins | |
| JP2008268186A (ja) | 磁気センサーの感度向上材料及び方法 | |
| Liu et al. | Nanovehicles based bioassay labels | |
| Chen et al. | Covalent conjugation of avidin with dye-doped silica nanopaticles and preparation of high density avidin nanoparticles as photostable bioprobes | |
| Özkul et al. | Unravelling the potential of magnetic nanoparticles: a comprehensive review of design and applications in analytical chemistry | |
| Cháfer-Pericás et al. | Functionalized inorganic nanoparticles used as labels in solid-phase immunoassays | |
| Woolley et al. | From particle to platelet: optimization of a stable, high brightness fluorescent nanoparticle based cell detection platform | |
| US20060263906A1 (en) | Tri-functional nanospheres | |
| EP1957977A1 (en) | Sensitive magnetic catch assay by building a strong binding couple | |
| JP2014149199A (ja) | ペプチドプローブ及び当該ペプチドプローブを利用した被検物質の測定方法 | |
| US20110294110A1 (en) | Set of magnetic labels | |
| Hainfeld et al. | Nanoparticle molecular labels | |
| JP2010002393A (ja) | 標的物質の検出方法 | |
| JP5147452B2 (ja) | 磁気バイオセンサーを利用した標的物質検出方法及びキット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |